Application of combination of oncopoxvirus and immune checkpoint PD-L1 / TDO2 inhibitor in preparation of antitumor drugs
By combining the oncolytic poxvirus rVV-CCL5 with the immune checkpoint PD-L1/TDO2 inhibitor, the problem of poor anti-tumor treatment in the prior art was solved, significantly reducing the tumor size and prolonging survival, and achieving tumor Immune reversal of the microenvironment and improvement of anti-tumor effects.
Patent Information
- Application Number
- CN202411102033.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-12-06
AI Technical Summary
The existing oncolytic virus and immune checkpoint inhibitors are used alone in anti-tumor treatment, and it is difficult to effectively reverse the immunosuppressive state of the tumor microenvironment, resulting in poor treatment effects.
The oncolytic poxvirus rVV-CCL5 is used in combination with the immune checkpoint PD-L1/TDO2 inhibitor. By increasing the expression of PD-L1 and TDO2, chemotaxis T lymphocytes and macrophages are infiltrated into the tumor microenvironment, reversing immunosuppression state, enhance anti-tumor effect.
Significantly reduce tumor size, prolong the overall survival of mice, improve the anti-tumor effect of PD-L1/TDO2 inhibitors, convert "cold tumor" into "hot tumor", significantly kill tumor cells, and show better treatment Effect.
Smart Images

Figure CN119074930A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of anti-tumor pharmaceutical compositions, and specifically, relates to the application of oncolytic poxvirus and immune checkpoint PD-L1 / TDO2 inhibitors in anti-tumor applications. Background Art
[0002] In recent years, due to the limitations of oncolytic virus therapy and immune checkpoint inhibitors in treating tumors alone, the combination of the two has gradually become a hot topic in immunotherapy. Existing research evidence shows that oncolytic viruses can enhance the response rate of tumors to immune checkpoint inhibitor treatments. In clinical studies, the combined use of oncolytic viruses and immune checkpoint inhibitors such as programmed cell death-Ligand 1 (PD-L1) inhibitors or CTLA-4 inhibitors has shown excellent anti-tumor therapeutic effects.
[0003] The oncolytic poxvirus rVV-CCL5 constructed by the inventor's research group in the early stage has been awarded a national invention patent (CN107164337A). The oncolytic poxvirus rVV-CCL5 has a good anti-tumor effect. If its anti-tumor effect can be further improved, it will be of great significance for obtaining better drug research for tumor treatment. Summary of the invention
[0004] When the inventors used the oncolytic poxvirus rVV-CCL5 constructed in the early stage (the oncolytic poxviruses described below are all oncolytic poxvirus rVV-CCL5 disclosed in patent CN107164337A) for in vitro experiments, they confirmed that after infecting the MC38 colorectal cancer (CRC) cell line, the expression of immune checkpoint molecules PD-L1 and tryptophan 2,3-dioxygenase 2 (TDO2) was significantly changed, which may be beneficial to reversing the immunosuppressive state of the solid tumor microenvironment. On this basis, the inventors have obtained a drug that combines oncolytic poxvirus rVV-CCL5 with immune checkpoint PD-L1 inhibitors and immune checkpoint TDO2 through a large number of experimental studies. The drug can be used in the treatment of rectal cancer. Compared with the use of oncolytic poxvirus rVV-CCL5 alone, or the use of immune checkpoint PD-L1 inhibitors and immune checkpoint TDO2 inhibitors alone, the combination of oncolytic poxvirus rVV-CCL5 and PD-L1 / TDO2 inhibitors showed stronger anti-tumor effects, including significantly reducing the tumor size of tumor-bearing mice and significantly increasing the overall survival of tumor-bearing mice.
[0005] Based on the above research, the present invention provides, on the one hand, the use of oncolytic poxvirus and immune checkpoint PD-L1 / TDO2 inhibitors in the preparation of anti-tumor drugs, and on the other hand, provides an anti-tumor drug comprising oncolytic poxvirus and immune checkpoint PD-L1 / TDO2 inhibitors.
[0006] Furthermore, the oncolytic poxvirus is a WR strain oncolytic poxvirus containing human CCL5 and human SSTR2 genes.
[0007] Furthermore, the oncolytic poxvirus is oncolytic poxvirus rVV-CCL5.
[0008] Furthermore, the tumor is a cold tumor.
[0009] Furthermore, the tumor is rectal cancer.
[0010] Beneficial effects of the present invention:
[0011] The present invention combines oncolytic poxvirus, immune checkpoint PD-L1 inhibitor and immune checkpoint TDO2 inhibitor. When used as a drug for the treatment of rectal cancer, the resulting drug can chemotactic T lymphocytes, macrophages, etc. to infiltrate into TME, transforming "cold tumors" into "hot tumors", effectively reversing the immunosuppressive state of TME, enhancing the anti-tumor effect of PD-L1 / TDO2 inhibitors, showing a significant tumor-killing effect, and showing better therapeutic effects in the early stages of treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 The diagrams show the changes in the protein levels of TDO2 and PD-L1 in the tumors of two groups of tumor-bearing mice; the left figure is a schematic diagram of the TDO2 and PD-L1 bands detected by Western blotting, the middle figure is a protein quantification diagram of the TDO2 band analyzed by ImageJ, and the right figure is a protein quantification diagram of the PD-L band analyzed by ImageJ;
[0013] Figure 2 This is a comparison chart of tumor changes in tumor-bearing mice;
[0014] Figure 3 are the tumor growth curves of four groups of tumor-bearing mice;
[0015] Figure 4 is the result of flow cytometry analysis;
[0016] Figure 5 is the proportion of DCs and NK cells in the spleen in each treatment group determined by flow cytometry;
[0017] Figure 6 are the flow cytometry analysis results of representative samples;
[0018] Figure 7 CD8 + Memory T cells, CD4 + Memory cells, IFN-γ + CD8 + Statistical graph of the proportion of T cells and Tregs cells in each treatment group;
[0019] Figure 8 is the flow cytometry diagram of MDSCs and their immunophenotyping G-MDSC and M-MDSC;
[0020] Fig. 9 is the flow cytometric analysis results of representative samples of each group of TAMs and their immunophenotyping TAM1 and TAM2 flow cytometry;
[0021] Fig.10 It is a statistical graph of the proportion of MDSCs, M-MDSCs and G-MDSCs in the spleen in each treatment group determined by flow cytometry and a graph of the percentage of MDSCs by immunophenotyping;
[0022] Fig.11 It is the statistical graph of the proportion of TAMs, TAM1 and TAM2 in the spleen in each treatment group determined by flow cytometry and the percentage graph of immunophenotyping in TAMs;
[0023] Fig.12 LAG-3 + PD-1 + CD8'T cells, TIM-3 + PD-1 + CD8'T cells, CTLA4 + PD-1 + CD8 + Tcells and TIGIT + PD-1 + CD8 + Flow cytometry of representative samples from each group of Tcells;
[0024] Fig.13 It is LAG-3 + PD-1 + TIM-3 + PD-1 + , CTLA4 + PD-1 + and TIGIT + PD-1 + Phenotype of CD8 + Statistics of the proportion of Tcells;
[0025] Fig.14The mRNA expression levels of tumor-related genes in each group of tumor tissues were detected by qRT-PCR; Figure A shows the mRNA expression levels of related genes in the tumor microenvironment, and Figure B shows the mRNA expression levels of tumor apoptosis-related genes; in the figure, * Taking the Mock group as the benchmark, * P<0.05, ** P<0.01, *** P < 0.001; # Taking the rVV-CCL5 group as the benchmark, # P<0.05, ## P<0.01, ### P < 0.001; ▲ Taking the αPD-L1Ab+TDO2Inhibitor group as the benchmark, ▲ P<0.05, ▲▲ P<0.01, ▲▲▲ P < 0.001;
[0026] Fig.15 The ELISA method is used to detect the concentration of tryptophan and kynurenine in mouse serum; Figure A shows the concentration of tryptophan in mouse serum; Figure B shows the concentration of kynurenine in mouse serum; in the figure, * Taking the Mock group as the benchmark, * P<0.05, ** P<0.01, *** P < 0.001; # Taking the rVV-CCL5 group as the benchmark, # P<0.05, ## P<0.01, ### P < 0.001; ▲ Taking the αPD-L1Ab+TDO2Inhibitor group as the benchmark, ▲ P<0.05, ▲▲ P<0.01, ▲▲▲ P < 0.001;
[0027] Fig.16 Immunofluorescence images of TDO2, PD-L1, CCL5, CD3, and F4 / 80 in mouse tumor tissues;
[0028] Fig.17 is the expression rate of TDO2, PD-L1, CCL5, CD3, and F4 / 80 antigen epitopes in mouse tumor tissue. * Taking the Mock group as the benchmark, * P<0.05, ** P<0.01, *** P < 0.001; #Taking the rVV-CCL5 group as the benchmark, # P<0.05, ## P<0.01, ### P < 0.001; ▲ Taking the αPD-L1Ab+TDO2Inhibitor group as the benchmark, ▲ P<0.05, ▲▲ P<0.01, ▲▲▲ P < 0.001;
[0029] Fig.18 The differential gene analysis and enrichment pathways of T cells in the combined treatment group and rVV-CCL5 group; Figure A is the differentially expressed gene analysis-volcano map; Figure B is the GO enrichment analysis-bubble map;
[0030] Fig.19 The differential gene analysis and enrichment pathways of T cells in the combined treatment group and a PD-L1Ab+TDO2Inhibitor group; Figure A is the differentially expressed gene analysis-volcano map; Figure B is the GO enrichment analysis-bubble map;
[0031] Fig. 20 Figure 1 is the differential gene enrichment pathway of Fibroblasts in the combined treatment group compared with the Mock group and the a PD-L1Ab+TDO2Inhibitor group; Figure A is the GO enrichment analysis-bubble diagram of the combined treatment group and the Mock group; Figure B is the GO enrichment analysis-bubble diagram of the combined treatment group and the a PD-L1Ab+TDO2Inhibitor group;
[0032] Fig.21 Figure 1 is a cell re-clustering analysis diagram; Figure A is a classification display diagram of T cell subsets in each group; Figure B is the proportion of each cluster in the total T cells in each tissue; Figure C is a volcano diagram of the difference in marker gene multiples in different cell populations; Figure D is the expression of Ccl5 gene in T cells in each tissue. DETAILED DESCRIPTION
[0033] In order to make the objectives, technical solutions and beneficial effects of the present invention clearer, the preferred embodiments of the present invention will be described in detail below to facilitate understanding by technicians.
[0034] The inventors have found through a large number of experimental studies that the oncolytic poxvirus rVV-CCL5 disclosed in the patent with publication number CN107164337A combined with the immune checkpoint PD-L1 / TDO2 inhibitor has a good therapeutic effect on rectal cancer when used as an anti-tumor drug. The potential mechanism of action may be that the recombinant oncolytic poxvirus rVV-CCL5 increases the expression of PD-L1, TDO2 and CCL5 in the colorectal cancer tumor microenvironment, chemotactic T lymphocytes, macrophages, etc. to infiltrate into the tumor microenvironment, and transforms the "cold tumor" into a "hot tumor", effectively reversing the immunosuppressive state of the mouse tumor microenvironment, thereby enhancing the anti-tumor effect of PD-L1 / TDO2 inhibitors. This research result suggests that rVV-CCL5 combined with immune checkpoint PD-L1 / TDO2 inhibitors can produce a synergistic anti-tumor effect.
[0035] The embodiments of the present invention use MC38 cell line mouse CRC as an experimental model to verify the anti-tumor effect of recombinant oncolytic poxvirus rVV-CCL5 combined with immune checkpoint TDO2 / PD-L1 inhibitor in the treatment of CRC, and study the anti-tumor mechanism of rVV-CCL5 combined with TDO2 / PD-L1 inhibitor.
[0036] First, we explored the direct anti-tumor effect and immune response induced by rVV-CCL5, and whether rVV-CCL5 significantly affected the expression of PD-L1 and TDO2 in the MC38 mouse CRC model. Then, we evaluated the anti-tumor effect of rVV-CCL5 combined with immune checkpoint PD-L1 / TDO2 inhibitors in the treatment of CRC, clarified whether the combined therapy was beneficial to improve the state of systemic immunosuppression, reverse TME and affect tryptophan metabolism, and explored the potential mechanism of the synergistic effect of rVV-CCL5 combined with PD-L1 / TDO2 inhibitors in the treatment of CRC.
[0037] Example 1 Construction of MC38 cell line mouse CRC model, using qRT-PCR and Western Blot to preliminarily verify the effect of rVV-CCL5 treatment on increasing the expression levels of PD-L1 and TDO2 in tumors
[0038] 1. Construction of MC38 cell line mouse CRC model:
[0039] (1) Preparation of MC38 cell suspension: MC38 cells with good growth status and a growth density of about 80% were washed twice with PBS, and 3 mL of trypsin was added for digestion. The cells were placed in an incubator for about three minutes, and then placed on an inverted phase contrast microscope to observe the digestion status of the cells. The bottle wall was tapped gently. After the bottom cells were basically digested, 3 mL of complete culture medium was immediately added to terminate the digestion. The cell suspension was collected in a 15 mL centrifuge tube. After centrifugation at 1000 rpm for 5 min, the supernatant was discarded, and the bottom cells were resuspended twice with pre-cooled sterile PBS. After centrifugation, 1 mL of PBS was added for resuspending and counting. The cell density was adjusted to 1×10 7 The cell suspension was stored on ice.
[0040] (2) Subcutaneous inoculation: On the mouse operating table, fix the mouse with your left hand, use a shaver to shave the hair on the right back of the mouse, and wipe the subcutaneous area of the right rib back of the mouse with 75% alcohol. During inoculation, use a pipette to completely disperse and mix the cells, use a 1mL syringe to absorb the cell suspension, and then inoculate it subcutaneously after wiping with alcohol. The injection volume is about 0.1mL, and the number of inoculated cells is about 1×10 6 indivual.
[0041] (3) Treatment model of subcutaneous tumors in C57BL / 6 mice: The first batch of experiments consisted of 3 mice in each group, divided into 2 groups, and marked as PBS control group (Mock) and oncolytic virus treatment group (rVV-CCL5). After grouping, each group of mice was treated for the first time, and the first treatment time was set as day 0. The treatment method of the PBS control group (Mock) was the same as that of the oncolytic virus treatment group (rVV-CCL5). The oncolytic virus was diluted with PBS to a titer of 5×10 6 pfu / mL. Each mouse was injected with 100uL of oncolytic virus or PBS at multiple points. The second batch of experiments had three mice in each group, and was divided into 3 groups, which were labeled as PBS control group (Mock), oncolytic virus treatment group (rVV-CCL5-High) and oncolytic virus treatment group (rVV-CCL5-Low). The rVV-CCL5-High group was injected with a higher concentration of the virus (4×10 6 pfu / 100uL, and the rVV-CCL5-Low group was injected with a lower concentration of the virus (2×10 6 pfu / 100uL), and the Mock group was injected with 100uL PBS.
[0042] (4) The length and short diameters of each mouse's tumor were recorded before administration, and again five days after administration. The growth status, mental state, and weight of the mice were observed every other day, as well as whether the tumor area showed any changes such as redness, swelling, and ulceration, in order to evaluate the therapeutic effect of each group of drugs and to measure whether each group of drugs would produce side effects.
[0043] (5) Mouse tissue sampling: Five days after administration, according to the experimental requirements of each group, prepare a number of sterilized ophthalmic surgical scissors and ophthalmic forceps, prepare 15mL sterile centrifuge tubes filled with sterile pre-cooled PBS, 1.5mL EP tubes filled with RNA later, and 5mL EP tubes filled with 4% paraformaldehyde and mark them with numbers. First, fix the mouse with the right hand, hold the forceps with the left hand and remove the eyeball to collect blood. The blood sample is left at room temperature for more than 1 hour, centrifuged at 3000rpm for 10 minutes, and the supernatant is serum, which is stored in a -20℃ refrigerator. After blood collection, the mice in each group are killed by cervical dislocation, and the mice are fixed on a foam board with their abdomen facing outward. The internal peritoneum is cut open with ophthalmic scissors. Use forceps to find the spleen on the side of the abdomen, gently peel off the fat and other adhesions on the spleen, and immediately put the spleen into a 15mL centrifuge tube filled with pre-cooled PBS. Subsequently, the mouse was turned over with its back facing up and fixed. The skin near the tumor was cut with ophthalmic scissors and tweezers. The complete tumor was slowly peeled off with tweezers and placed on ice. After the samples of each group were collected, they were placed on a calibration plate to compare the tumor size. The tumor was then cut into multiple small pieces with ophthalmic scissors and placed in 1.5 mL EP tubes containing RNA later and 4% paraformaldehyde.
[0044] 2. Real-time fluorescence quantitative PCR:
[0045] (1) Total RNA extraction from tumor tissue
[0046] a. Take out the tumor tissue cut into small pieces from the RNA later solution, dry the residual solution on the surface with absorbent paper, put it into a sterile 1.5ml EP tube, add lysis buffer Buffer RLF, grind the tumor tissue into a homogenate with a tissue grinder, and place it on ice in the lysis buffer for half an hour.
[0047] b. Place the DNA filter column in a 2 mL collection tube, then transfer the lysate to the filter column and centrifuge at 14,000 rpm for 2 minutes.
[0048] c. Discard the filter column, add 500 μL 70% ethanol to the filtrate, and pipette up and down 5 times.
[0049] d. Place the FastPure RNA column in a 2 mL collection tube to ensure that it does not contain RNase. Transfer the filtrate mixture to the FastPure RNA column, centrifuge at 12,000 rpm for 60 seconds, and discard the waste liquid in the collection tube.
[0050] e. Add buffer RW1F to the FastPure RNA column and centrifuge at 12,000 rpm for 60 seconds.
[0051] f. Pour 500uL of wash buffer RW2 into the FastPure RNA column and centrifuge at 12000rpm for 60s. Remove the adsorption column from the collection tube and discard the waste liquid.
[0052] g. Repeat step f.
[0053] h. Transfer FastPure RNA to a new RNase-Free centrifuge tube and let it stand for 10 minutes. Then slowly add 40uL ddH2O to the center of the adsorption membrane. After standing at room temperature for 2 minutes, centrifuge at 12000rpm for one minute. The RNase-Free centrifuge tube contains RNA, which can be reverse transcribed immediately or stored in a -80 refrigerator.
[0054] (2) Reverse transcription
[0055] a. Take out the RNA template and place it on ice to thaw.
[0056] b. Use Nanodrop 2000 to measure the purity and concentration of the extracted RNA and determine the volume of RNA required to quantify 2ug RNA.
[0057] c. Dissolve the reagents in the reverse transcription kit at room temperature, add the reverse transcription reaction system to a 200uL EP tube according to the instructions of the reverse transcription kit of Qingke, and centrifuge briefly in a low-speed centrifuge to mix.
[0058] d. Incubation: 42°C for 2 min, then 60°C for 5 min.
[0059] e. Quickly remove the EP tube and prepare the reverse transcription reaction system
[0060] f. Centrifuge briefly to mix.
[0061] g. Set up the reaction program on the PCR instrument:
[0062] h. After the reverse transcription reaction is completed, cDNA products will be generated and can be used immediately for qRT-PCR, or stored in a -20℃ refrigerator for short-term storage, or in a -80℃ refrigerator for long-term storage.
[0063] (3) qRT-PCR
[0064] a. The cDNA template was thawed on ice in advance.
[0065] b. The entire experimental process must be performed on ice, and the qRT-PCR reaction system must be prepared according to Takara's qRT-PCR kit.
[0066] c. After the above qRT-PCR reaction system is prepared, add it to the eight-tube strip, and repeat 3 wells for each sample. After adding the sample, put the eight-tube strip into the centrifuge, centrifuge at 5000 rpm for 1 min, set the reaction program, put the eight-tube strip into the instrument, and perform the reaction on the machine.
[0067] d. Obtain the Ct value of the sample based on the fluorescence signal collected by the real-time fluorescence quantification instrument, and calculate the expression level of mRNA in each tumor tissue using the 2-ΔΔCt method.
[0068] 3. Western Blot:
[0069] (1) Extraction of total protein from tumor tissue
[0070] a. Cut the tumor tissue into small pieces and place them into a sterile 1.5 mL EP tube. The entire extraction process must be performed on ice.
[0071] b. Prepare lysis mixture with a ratio of RIPA lysis solution: protease inhibitor = 100:1. Add 300 μL of the mixture to each EP tube. Grind the tissue into a homogenate using a tissue grinder disinfected with alcohol. Place the tissue on ice for lysis for half an hour. Use a pipette to transfer all the liquid in the culture bottle to a new 1.5 mL EP tube.
[0072] c. Set the centrifugation conditions of the high-speed centrifuge to 4°C, 12,000 rpm, and 10 min. Place the EP tube in the centrifuge. After centrifugation, take out the EP tube and carefully collect the total protein supernatant with a pipette. Transfer it to a new EP tube, taking care not to suck up the precipitate.
[0073] d. After the extracted total protein is labeled as necessary, the protein concentration can be measured immediately or stored in a -80℃ refrigerator.
[0074] (2) Protein quantification - BCA method
[0075] Make a standard curve:
[0076] a. Use protein standard preparation solution to prepare 30 mg BSA protein standard into a 0.5 mg / ml standard solution.
[0077] 200uL of BCA working solution was prepared in each well at a ratio of 50:1: solution A (solution A is a mixture of 1% BCA disodium salt, 0.4% sodium hydroxide, 0.16% sodium tartrate, 2% anhydrous sodium carbonate, and 0.95% sodium bicarbonate, pH = 11.25; solution B is 4% copper sulfate).
[0078] b. Add the standard sample to the 96-well plate according to the concentration gradient of the standard sample indicated in the instructions of the BCA Protein Concentration Assay Kit (Enhanced) of Beyotime, and set up 3 replicate wells for the standard curve wells.
[0079] c. First add 2 μL of the sample protein to the test well, and then add 18 μL of PBS to make up. Set up 3 replicate wells for the sample wells.
[0080] d. Set the ELISA reader to a constant temperature of 37°C and place the 96-well plate in it for incubation for 30 minutes.
[0081] e. After incubation, measure the OD value at a wavelength of 562nm with a microplate reader, draw a standard curve based on the concentration gradient of the standard and the OD value, calculate the concentration of the protein to be tested, and determine the volume of protein, PBS buffer volume, and 5x loading buffer required to be added to the 20μL loading system.
[0082] (3) Protein denaturation
[0083] The protein, PBS and 5x loading buffer volumes required for the 20 μL loading system calculated above were added into the EP tube in sequence. After being thoroughly mixed using a vortexer, the tube was placed in a 100°C metal bath apparatus for denaturation within 10 minutes and then stored in a -20°C refrigerator for short-term storage or -80°C for long-term storage.
[0084] (4) SDS-PAGE gel preparation
[0085] Preparation of separation gel and concentrated gel: First check whether the gel-making supporting plate and the rack are completely fitted and there is no leakage. Add separation gel to about 2 cm from the upper edge of the glass short plate, use anhydrous ethanol to press the gel surface, set the timer to 30 minutes, wait until the colloid is completely solidified, pour out the anhydrous ethanol, rinse with ultrapure water, absorb the residual water with absorbent paper, dry it, then fill the glass plate with concentrated gel, insert the comb. Leave it at room temperature until it is completely solidified.
[0086] (5) Electrophoresis
[0087] a. Clamp the prepared SDS-PAGE gel with an electrophoresis gel plate, put it into the electrophoresis tank, fill it with the prepared electrophoresis solution to submerge the glass plate, then slowly pull out the comb with both hands to ensure that the sample wells are flat and vertical, and use a pipette to add 5μL marker and 15μL protein sample respectively.
[0088] b. Turn on the power supply and adjust the electrophoresis condition of the electrophoresis apparatus to a constant voltage of 90V. After observing the bromophenol blue band running out of the concentrated gel, adjust the voltage to 120V and stop the electrophoresis when the band runs to the bottom of the glass plate.
[0089] (6) Transfer
[0090] a. Cut the PVDF membrane into the same size as the colloid in advance and soak it in methanol solution for 5 minutes.
[0091] b. Take the glass plate out of the electrophoresis tank and place it in the transfer solution prepared in advance. The transfer solution is in the order of sponge, filter paper, gel, PVDF membrane, filter paper, sponge from bottom to top according to the "sandwich model". Put the clamps in the transfer tank. Fill the transfer tank with transfer solution and set the transfer conditions to 100V for 1.5h.
[0092] c. During the entire transfer process, the transfer tank should be placed in an ice water bath to prevent overheating and protein transfer failure.
[0093] (7) Closed
[0094] After the transfer is completed, cut the PVDF membrane according to the position of the protein molecular weight, put it in the antibody incubation box, and then put it on the decolorization shaker, add 1×TBST solution prepared in advance with TBS and Tween 20 to wash the PVDF membrane three times. Then add 5% BSA blocking solution to the incubation box, and shake it slowly at room temperature for 1 hour on a horizontal shaker.
[0095] (8) Primary antibody incubation
[0096] Discard the blocking solution and wash the PVDF membrane three times with 1×TBST solution, 5 minutes each time. Then add the pre-prepared primary antibody solution (rabbit anti-TDO2 primary antibody, goat anti-PD-L1 primary antibody, mouse anti-β-actin primary antibody, all three antibodies are diluted with Beyotime's Western primary antibody diluent, the dilution ratio is 1:1000), and place it on a shaker at 4°C overnight, or at room temperature for 4 hours.
[0097] (9) Secondary antibody incubation
[0098] The primary antibody was recovered into a 15 mL centrifuge tube using a pipette, and the PVDF membrane was washed with 1× TBST solution on a shaker for 5 minutes, for a total of three washes. Then, the secondary antibodies corresponding to the primary antibody were added respectively, and the membranes were incubated on a shaker for 1 hour under room temperature with slow shaking.
[0099] (10) Development
[0100] Pipette off all the secondary antibodies, wash the PVDF membrane with 1×TBST solution on a shaker for 5 minutes, and wash three times in total. Prepare the chemiluminescent developer according to the ratio of 1:1 between solution A and solution B in the New Cyme ultrasensitive ECL chemiluminescent kit. Add the chemiluminescent developer to the PVDF membrane and develop it with a gel imager.
[0101] The changes in the protein levels of TDO2 and PD-L1 in the tumors of the two groups of tumor-bearing mice are shown in the attached figure. Figure 1 .pass Figure 1 It can be seen that intratumoral injection of recombinant oncolytic poxvirus rVV-CCL5 significantly affected the protein expression levels of TDO2 (P<0.01) and PD-L1 (P<0.001) in the MC38CRC model. After injection of recombinant oncolytic poxvirus rVV-CCL5, the protein expression levels of TDO2 and PD-L1 increased significantly.
[0102] Example 2 Anti-tumor effect of combined therapy of rVV-CCL5 and PD-L1 / TDO2 inhibitors
[0103] (1) Preparation of spleen cell single cell suspension
[0104] a. Place the mouse spleen on a 200-mesh sieve placed on a 50ml centrifuge tube, cut it into pieces with scissors, and grind it with the handle of a syringe, and rinse the sieve with an appropriate amount of PBS. Transfer the single-cell suspension to a 15ml centrifuge tube, centrifuge at 1500rpm for 5 minutes, discard the supernatant, and add 3ml of 1640 culture medium for resuspending.
[0105] b. Take another sterile 15ml centrifuge tube and add 4ml of lymphocyte separation solution. Tilt the test tube and lay it slightly flat. Pipette the prepared cell suspension and slowly add it into the centrifuge tube containing the separation solution. Do not break the separation interface between the two liquid surfaces. Centrifuge at 1500rpm, set low acceleration and deceleration, and centrifuge for 20 minutes.
[0106] c. Aspirate the middle cell layer, transfer to 4ml of the prepared red blood cell lysis buffer, gently blow and mix, lyse at room temperature for 5min, add an equal volume of 1640 culture medium to terminate the lysis, and centrifuge at 1000rpm for 10min. Discard the supernatant, resuspend the cells with 3ml stain buffer, and centrifuge at 1000rpm for 5min (twice). Subsequently, resuspend the cells with 1ml stain buffer and count the cells. Take 10ul of cells and add them to 90ul of 1640 culture medium, and take 10ul of the cell suspension to calculate the number of cells.
[0107] (2) Trypan blue staining
[0108] Take 10ul of staining solution and add it to the remaining 90ul of cell suspension, mix well, stain for more than 3 minutes, and then take 10ul of the mixture and add it to the cell counting plate under the microscope for observation. Dead cells are stained in obvious blue, and live cells are colorless and transparent. Calculate the live cell ratio. To count cell viability, generally count the total cells and dead cells.
[0109] (3) Flow cytometry antibody staining
[0110] a. Use stain buffer to adjust the cell concentration of each group to 1x107 cells / ml, and dispense 100ul into each flow tube.
[0111] b. Block Fc receptors: add 0.5-1ug BD Fc Block (α-CD16 / 32Ab) to 100ul staining buffer, incubate at 4℃ for 15 minutes, wash the cells with 1ml PBS / staining buffer, centrifuge at 1000rpm at 4℃ for 5 minutes, and remove the supernatant.
[0112] c. Cell surface antibody staining: resuspend the cells with 100ul staining buffer, add cell surface antibodies CD45, CD3, CD8, CD4, CD44, Gr1, CD11b respectively, and incubate at 4℃ for 30 minutes. Add 1ml pbs / staining buffer to wash the cells once, centrifuge at 1500rpm for 5 minutes. Add 300ul staining buffer to resuspend the cells, then add DAPI and analyze on the microscope.
[0113] (4) In vitro experiments to evaluate the anti-tumor effects and mechanisms of combined therapy of rVV-CCL5 and PD-L1 / TDO2 inhibitors
[0114] Four control experiments were set up (Mock group, rVV-CCL5 group, αPD-L1Ab+TDO2Inhibitor group, rVV-CCL5+αPD-L1Ab+TDO2Inhibitor group). Mice with successful tumor bearing were randomly selected for grouping, and D7 was the time of the first treatment. Thereafter, treatment was performed every three days for a total of three treatments. Oncolytic virus was injected only on the first treatment day. The growth status of mice, the length and short diameter of the tumor, and the final tumor size were recorded, and samples were collected on D16.
[0115] The tumor changes of the four groups of tumor-bearing mice are shown in the attached figure. Figure 2 , the tumor growth curves of the four groups of tumor-bearing mice are shown in Figure 2 Figure 3 ,pass Figure 2 and Figure 3It can be seen that the rVV-CCL5 group has a certain ability to inhibit tumor growth compared with the Mock group in the early stage of treatment, but the effect is not good in the later stage of treatment, and the tumor growth curve shows an upward trend. The combined treatment group, i.e., the rVV-CCL5+αPD-L1Ab+TDO2Inhibitor treatment group and the antibody group, i.e., the αPD-L1Ab+TDO2Inhibitor treatment group, both showed significant tumor killing effects, and in the early stage of treatment, the combined treatment group showed better therapeutic effects.
[0116] Example 3 Flow cytometry was used to preliminarily evaluate the effects of intratumoral injection of different titers of rVV-CCL5 on positive immune cell phenotypes (CD8+T cells, CD8+memory T cells, CD4+memory T cells) and negative regulatory immune cell phenotypes (MDSCs)
[0117] (1) Preparation of spleen cell single cell suspension and trypan blue staining, the steps are the same as Example 2.
[0118] (2) Flow cytometry antibody staining
[0119] The cell concentration of each group was adjusted to 1x10 7 / mL, take 100uL and dispense it into each flow tube.
[0120] Block Fc receptors: add 0.5-1ug BD Fc Block (αCD16 / 32Ab) to 100uL staining buffer, incubate at 4℃ for 15 minutes, wash cells with 1mL PBS / staining buffer, centrifuge at 1000rpm at 4℃ for 5 minutes, and remove the supernatant.
[0121] (3) Cell surface staining: Resuspend the cells in 100uL staining buffer, add cell surface antibodies, and incubate at 4°C for 30 minutes.
[0122] Wash the cells once with 1 mL PBS / staining buffer and centrifuge at 1500 rpm for 5 minutes. Resuspend the cells with 300 uL staining buffer and analyze on the analyzer.
[0123] (4) Intracellular factor staining
[0124] a. Prepare working solution: TF Fix / perm Buffer (4×) and TF diluent buffer to make 1× working solution, invert five times.
[0125] b. Perform surface cytokine staining first. Cell staining should be performed on ice. Wash once with 1 mL PBS and centrifuge at 1000 rpm for 5 min. For cell surface factor staining, incubate at 4°C in the dark for 15 min.
[0126] c. Add 250uL 1×Fixation / perm Buffer to each test tube to resuspend the cells, vortex to mix evenly, and incubate at room temperature in the dark for 30 minutes.
[0127] d. Add 1 mL of 1× perm / wash buffer to each test tube and centrifuge at 350 g at 4°C for 6 minutes.
[0128] e. Draw out the supernatant, add 1 mL of 1× perm / wash Buffer for washing, centrifuge at 300 g for 5 minutes at 4°C, and discard the supernatant.
[0129] f. Intracellular factor staining: Add 100uL 1×perm / wash Buffer to the cell sample and resuspend it, then add IFN-γ antibody and CD206 antibody, vortex for 10 seconds, and incubate at 4℃ in the dark for 30 minutes.
[0130] g. Vortex briefly before washing, wash with 1 mL 1×perm / wash, and centrifuge at 1500 rpm for 5 min.
[0131] h. Remove the supernatant, resuspend with 300uL PBS, and detect on the instrument.
[0132] (5) Intrinsic factor staining
[0133] a. Perform surface cytokine staining first. Cell staining should be performed on ice. Wash once with 1 mL PBS and centrifuge at 1000 rpm for 5 min.
[0134] b. Resuspend the cells with 200uL Fixation / permeabilization working solution, vortex to mix evenly, and place at 4℃ for 30 minutes.
[0135] c. Add 400uL Foxp3 buffer and centrifuge at 1500rpm for 5 minutes.
[0136] d. Repeat step 3 and wash again.
[0137] e. Aspirate and discard the supernatant, add 100uL 1×Foxp3 permeabilization buffer to resuspend the cells, then add 0.5uL PE anti-Foxp3 antibody, vortex for 10s to mix evenly, and incubate in the dark for 30 minutes.
[0138] f. After completion, add 400uL Foxp3 permeabilization buffer to each tube to wash the cells, centrifuge at 1500rpm for 5 minutes, discard the supernatant, resuspend with 300uL PBS, and detect on the instrument.
[0139] (6) Result analysis: FlowJo software was used to circle the cell populations labeled with each fluorescent antibody combination.
[0140] GraphPad Prism v9 software was used for statistical analysis of the results.
[0141] The changes in the phenotypes of lymphocytes in the spleens of the four groups of tumor-bearing mice are shown in the attached figure. Figure 4-Figure 13 ,pass Figure 4-Figure 7 It can be seen that the combined treatment of rVV-CCL5+αPD-L1Ab+TDO2Inhibitor increased the levels of positive immune cell subsets (including DCs, NK cells, CD8+memory T cells, IFN-γ+CD8+T cells) in the spleen; Figure 8-Figure 11 It can be seen that the combined treatment reduced the immunosuppressive cell subsets (including MDSCs, TAMs, and Tregs); Figure 12-13 It can be seen that combined therapy reduced the proportion of exhausted PD-1+CD8+T cells (including LAG-3+, CTLA4+, TIGIT+).
[0142] Example 4 qRT-PCR detection of the expression levels of immunity and apoptosis-related genes in mouse tumor tissues
[0143] qRT-PCR is the same as the steps of real-time fluorescence quantitative PCR in Example 1;
[0144] The mRNA expression of tumor-related genes in the four groups of tumor-bearing mice is shown in the attached figure. Fig.14 , where Figure A shows the mRNA expression levels of related genes in the tumor microenvironment, and Figure B shows the mRNA expression levels of tumor apoptosis-related genes. It can be seen from Figures A and B that compared with the single treatment group and the Mock group, the combined treatment group helps to increase the mRNA expression levels of PD-L1, TDO2, CCL5, IFN-γ and apoptosis-related genes Granzme B, Perforin, and P53 in the tumor microenvironment, and reduce the mRNA expression level of VEGFA.
[0145] Example 5 ELISA assay to detect the metabolic levels of tryptophan and kynurenine intermediates of TDO2 metabolism in serum
[0146] (1) Dilution of standard: Dilution of standard was performed according to the instructions of mouse tryptophan (TRP) ELISA kit and mouse kynurenine ELISA kit.
[0147] (2) Sample addition: Take out the serum frozen in the -20°C refrigerator in Example 1 and thaw it at room temperature. Take out the ELISA coated plate, and set up blank wells, standard wells, and test sample wells according to the number of grouped samples. The blank control wells do not contain samples and ELISA reagents, and the other steps are the same. According to the dilution gradient of the standard, first add 50 μL of the sample to the ELISA coated plate, first add 40 μL of the sample diluent to the test sample well, and then add 10 μL of the test sample, which is equivalent to a 5-fold dilution. Try to add the sample to the bottom of the ELISA plate well and shake to mix evenly.
[0148] (3) Incubation: After sealing with a sealing film, place the plate in an incubator at 37°C for 30 minutes.
[0149] (4) Liquid preparation: In a 50 mL centrifuge tube, dilute the 30-fold concentrated washing solution 30-fold with distilled water and place it on the operating table for later use.
[0150] (5) Washing: Gently peel off the sealing film, shake off the liquid in the wells vigorously, then use a pipette to fill the wells with washing solution. After standing for 30 seconds, shake off the liquid in the wells, and then pat dry on absorbent paper. Repeat 5 times.
[0151] (6) Add enzyme: Use a pipette to add 50 μL of enzyme-labeled reagent to the standard well and the sample well.
[0152] (7) Incubation: Perform the same operation as step (3).
[0153] (8) Washing: perform the same operation as (5).
[0154] (9) Color development: First add 50 μL of color developer A to the well, then add 50 μL of color developer B to the well, shake by hand until mixed evenly, and place in an incubator at 37°C in the dark for 10 minutes.
[0155] (10) Stopping: Add 50 μL of stop solution to each well. The liquid will turn from blue to yellow.
[0156] (11) Determination: The absorbance value (OD value) of each well was measured in turn at a wavelength of 450 nm in an ELISA instrument. The blank well value was set for zero adjustment. The measurement process was completed within 15 minutes after the addition of the stop solution.
[0157] (12) Calculation: Draw a standard curve with the standard concentration on the horizontal axis and the OD value on the vertical axis. Calculate the corresponding concentration based on the standard curve and the OD value of the sample to be tested, and then multiply it by the dilution factor to get the actual concentration of the sample.
[0158] The changes in serum tryptophan and kynurenine concentrations of the four groups of tumor-bearing mice are shown in the attached figure. Fig.15 ,pass Fig.15 It can be seen that the concentrations of TDO2 metabolic intermediates Trp and Kyn in the serum of the combined treatment group were significantly reduced compared with the single treatment group and the Mock group.
[0159] Example 6 Multiple fluorescent immunohistochemistry detection of PD-L1, TDO2, CCL5, CD3, F4 / 80 antigen epitope distribution and expression rate on tumor tissue after treatment
[0160] (1) Preparation of tissue wax blocks and sections
[0161] a. Tissue preparation: Take the tumor tissue obtained in Example 2 and cut it into small pieces.
[0162] b. Fixation: After the tissue is removed from the body, place it in a 4% formaldehyde solution within 30 minutes. Allow the fixative to completely immerse the tissue and leave it at room temperature for 24 hours.
[0163] c. Water washing: After fixation, thoroughly rinse off the tissue fixative with water.
[0164] d. Dehydration: Use ethanol as a dehydrating agent and adopt a gradient alcohol dehydration method to replace the water in the tissue.
[0165] e. Transparency: Use xylene as a transparent agent to soak the tissue sample. After each soaking for 15 minutes, replace the xylene with new one and soak for another 15 minutes.
[0166] f. Wax immersion: First soak the tissue in soft wax for 30 minutes, then change to new soft wax and soak for 30 minutes, change to hard wax and soak for one and a half hours, then change to new hard wax and soak for one and a half hours.
[0167] g. Embedding: Wrap the wax-soaked tissue block in paraffin.
[0168] h. Slicing: Use a microtome to slice the wax block, adjust the slice thickness to 4 μm, and perform continuous slicing.
[0169] (2) Dewaxing of paraffin sections: sequentially place the sections in environmentally friendly dewaxing solution I for 10 min, environmentally friendly dewaxing solution II for 10 min, environmentally friendly dewaxing solution III for 10 min, anhydrous ethanol I for 5 min, anhydrous ethanol II for 5 min, anhydrous ethanol III for 5 min, and then wash with distilled water.
[0170] (3) Antigen retrieval: Place the slides on a decolorizing shaker containing PBS and shake for 5 minutes, washing three times in total. Be careful to prevent the slides from drying out during the antigen retrieval process.
[0171] (4) Circle drawing and hydrogen peroxide sealing: Use a histochemical pen to draw a circle around the tissue, then place the slices in a 3% hydrogen peroxide solution at room temperature and incubate for half an hour. Then place the slides on a decolorizing shaker containing PBS and shake for 5 minutes. Wash three times in total.
[0172] (5) Serum blocking: Remove the PBS on the slide and add BSA for blocking for half an hour.
[0173] (6) Incubation of multiple fluorescent histochemical antibodies: Remove BSA, add primary antibody solution (rabbit anti-CD3 primary antibody, rabbit anti-F4 / 80 primary antibody, rabbit anti-CCL5 primary antibody, goat anti-PD-L1 primary antibody, rabbit anti-TDO2 primary antibody)) on top, place in a humidified box, and incubate at 4°C overnight.
[0174] (7) Incubation with HRP-labeled secondary antibody (rabbit / sheep HRP-labeled secondary antibody): Place the slide on a decolorizing shaker containing PBS and shake for 5 minutes, washing three times in total. Add the HRP-labeled secondary antibody corresponding to the primary antibody to the slide and incubate at room temperature for 50 minutes.
[0175] (8) Add CY3-TSA (or 488-TSA, CY5-TSA): Place the slide on a decolorizing shaker containing PBS and shake for 5 minutes, washing three times in total. Add TSA to the slide, incubate at room temperature in the dark for 10 minutes, then place the slide on a decolorizing shaker containing TBST and shake for 5 minutes, washing three times in total.
[0176] (9) Microwave treatment: Place a repair box containing repair buffer in a microwave oven, place the tissue sections in the repair buffer, and heat them in the microwave. First, heat them on medium heat for 8 minutes, let them stand for 8 minutes, and then heat them on medium-low heat for 7 minutes.
[0177] (10) DAPI counterstaining of cell nuclei: Add DAPI staining solution to the slide and incubate at room temperature in the dark for 10 minutes
[0178] (11) Quenching tissue autofluorescence: Place the slide on a decolorizing shaker containing PBS and shake for 5 minutes, washing three times in total. Then add autofluorescence quencher B solution to the slide, incubate for 5 minutes, and rinse with running water for 10 minutes.
[0179] (12) Sealing: Seal the slides with anti-fluorescence quenching sealing medium.
[0180] (13) Image acquisition: Use 3DHISTECH software to acquire images.
[0181] The distribution of antigen epitopes of TDO2, PD-L1, CCL5, CD3, and F4 / 80 in the tumor tissues of the four groups of tumor-bearing mice is shown in the attached figure. Fig.16 and FourExpression rates of TDO2, PD-L1, CCL5, CD3, and F4 / 80 antigen epitopes in tumor tissues of tumor-bearing mice Fig.17 ,pass Fig.16 and Fig.17 It can be seen that oncolytic poxvirus rVV-CCL5 can promote the infiltration of macrophages and the expression of chemokine CCL5, and the combined treatment group is conducive to chemotactic infiltration of more T cells into the tumor microenvironment.
[0182] Example 7 Single-cell transcriptome sequencing illustrates the effect of combined therapy on TME.
[0183] (1) Six groups of C57BL / 6 subcutaneous colorectal cancer tumor samples after different treatments were collected and numbered as follows: A1: mock group, A2: rVV-CCL5 group, A3: TDO2inhibitor group, A4: αPD-L1Ab group, A5: TDO2inhibitor+αPD-L1Ab group, A6: rVV-CCL5+TDO2inhibitor+αPD-L1Ab group.
[0184] (2) After enzymatic hydrolysis of the tumor tissue, each sample was sorted by FACS to remove dead cells and perform cell quality inspection. Subsequently, single cells were labeled and libraries were constructed, and single-cell sequencing analysis was performed using Lianchuan Bio's 10X Genomics platform.
[0185] (3) The 10x genomics platform uses microfluidics technology to sort single cells, and then encapsulates gel beads with barcodes and primers and single cells in oil droplets; in the oil droplets, the gel beads dissolve to release reverse transcription oligos, and the cells are lysed to release mRNA, and the barcoded cDNA for sequencing is obtained through the SMART method; after the liquid oil layer is destroyed, the cDNA is used for subsequent library construction and detected using the Illumina sequencing platform.
[0186] (4) Data quality control: Based on the quality control and quantification of sequencing data by CellRanger, CellRanger will first align, filter and count the raw sequencing data, and then use Seurat software to eliminate the data with mitochondrial genes exceeding 25% in single cells.
[0187] (5) Graphical analysis of cell subpopulation clustering and dimensionality reduction: By using Seurat software, the built-in parameters are used to normalize the data and search for highly variable genes (the normalization algorithm used is: LogNormalize). Seurat then uses these calculated highly variable genes to perform downstream principal component analysis (PCA) calculations, and after obtaining the corresponding PCA values, it performs dimensionality reduction clustering and clustering analysis on the data based on these values. By default, the first 20 PCs of PCA are used for subsequent clustering and clustering analysis. After the principal component calculation is completed, Seurat will use the FindNeighbors function to cluster cells with similar expression patterns based on the results, and use the FindClusters function to define relatively close cells as the same cell subpopulation, i.e., cluster.
[0188] (6) After the clustering is completed, the UMAP (Uniform Manifold Approximation and Projection) dimensionality reduction algorithm is used to reduce the cell expression matrix data to a two-dimensional plane, and the data is distinguished by similarity to obtain the statistical results of cell clustering, which is used to assist us in accurately distinguishing cell types and subtypes and their visualization. The results obtained by UMAP represent the actual distance relationship between cell groups, and all cell subgroups are visualized separately according to samples, and the heterogeneity between different samples is discovered.
[0189] (7) Cell type annotation: Based on the highly expressed genes in each cluster, cell subpopulations of each cluster were identified through PanglaoDB and CellMarker websites and literature queries.
[0190] (8) Analysis of differentially expressed genes between the two groups and enrichment analysis of marker genes using Gene Ontology (GO) were performed. The bimod differential analysis algorithm was used with the conditions set to P < 0.01, the differential screening condition log2fc value: log2fc ≥ 0.26, and the expression ratio of the differential screening gene in at least one of the groups: 0.1. The GO enrichment analysis results were displayed in the form of a bubble chart using ggplot2.
[0191] The differential gene analysis and enrichment pathways of T cells in the combined treatment group and rVV-CCL5 group of tumor-bearing mice are shown in the attached figure. Fig.18 Differential gene analysis and enriched pathways of T cells in the combined treatment group and a PD-L1Ab+TDO2Inhibitor group Fig.19 Fibroblasts differentially enriched gene pathways in the combined treatment group compared with the Mock group and a PD-L1Ab+TDO2Inhibitor group Fig. 20 T cell repopulation analysis Fig.21 ; Fig.21 Figure A shows the classification of T cell subsets in each group, Figure B shows the proportion of each cluster in the total T cells of each tissue, Figure C shows the volcano map of the difference in marker genes of different cell populations, and Figure D shows the expression of Ccl5 gene in T cells of each tissue. Fig.18 It can be seen that the upregulated genes in the combined treatment group compared with the rVV-CCL5 group include: Eif5a, Tubb5, Cd74, Srsf7, H2-eb1, Lyz2, H2-Aa, Ccl2, Hspal1, and Ccl3, indicating that the combined treatment group has a more obvious inflammatory response than the rVV-CCL5 group, promoting the expression of MHC-II molecules on activated T lymphocytes and enhancing the ability to recognize tumor antigens. The pathway enrichment results of the differentially expressed genes in the combined treatment group compared with the rVV-CCL5 group were analyzed, and they were mainly enriched in protein binding, cytoplasm, nucleus, immune system process and other related pathways. Fig.19 It can be seen that the upregulated genes in the combined treatment group compared with the αPD-L1Ab+TDO2Inhibitor group include: Rps27, Pfn1, Ccl5, Hcst, Klf2, Gzmk, and Gzma, indicating that rVV-CCL5 can play a role in attracting immune cells such as T cells and NK cells to infiltrate tumor tissues. The pathway enrichment results of the differentially expressed genes in the combined treatment group compared with the αPD-L1Ab+TDO2Inhibitor group were analyzed, and they were mainly enriched in pathways such as protein binding, cell apoptosis, inflammatory response, positive regulation of T cell activation, and antiviral response. Fig. 20 It can be seen that the combined treatment group was enriched in antiviral response pathways, as well as immune system processes, innate immune responses, chemokine responses, immune responses, interferon responses and other immune-related pathways, proving that rVV-CCL5 has a good ability to reverse TME and stimulate the response of immune cells in tumors. Fig.21 It can be seen that cluster 0 in the combined treatment group (A6) and the rVV-CCL5 group (A2) occupies the largest proportion of total T cells, and is significantly higher than other groups. The top five highly expressed genes in the cluster 0 component are Gzma, Ccl5, Gzmk, Ly6c2, and Cd8b1. The expression level of Ccl5 in the combined treatment group and the rVV-CCL5 group was also significantly higher than that in other groups. Compared with other groups, the combined treatment group has a lower proportion of cluster 9, and cluster 9 highly expresses Foxp3, which is speculated to be a type of cell subset related to Treg cells. This shows that the combined treatment group has a higher proportion of positive immune T cell gene expression and a lower proportion of immunosuppressive T cell gene expression.
[0192] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.
Claims
1. The application of oncolytic poxvirus and immune checkpoint PD-L1 / TDO2 inhibitors in the preparation of anti-tumor drugs.
2. The use according to claim 1, characterized in that: The oncolytic poxvirus is a WR strain oncolytic poxvirus containing human CCL5 and human SSTR2 genes.
3. The use according to claim 2, characterized in that: The oncolytic poxvirus is a recombinant oncolytic poxvirus rVV-CCL5.
4. The use according to claim 1, characterized in that: The tumor is a cold tumor.
5. The use according to claim 1, characterized in that: The tumor is rectal cancer.
6. An anti-tumor drug, characterized in that: Including oncolytic poxvirus, immune checkpoint PD-L1 and immune checkpoint TDO2 inhibitors.
Citation Information
Patent Citations
Recombinant vaccinia virus containing genes CCL5 and SSTR2 and preparation method of recombinant vaccinia virus
CN107164337A
Anti-PD-L1 antibody and application thereof
CN114656565A
Cited By
Multifunctional nano preparation for reversing tumor immune microenvironment as well as preparation method and application of multifunctional nano preparation
CN120022242A
Multifunctional nano-preparation for reversing tumor immune microenvironment and preparation method and application thereof
CN120022242B
